PMV Pharma reports 33% ORR for rezatapopt in TP53 Y220C tumors; NDA for ovarian cancer planned Q1 2027

PMV Pharmaceuticals, Inc.

Overall ORR 33% (32/97 evaluable patients) across 8 tumor types; median duration of response 6.2 months.
Ovarian cancer cohort: 43% ORR (19/44), median DOR 7.6 months, includes one confirmed complete response.
Safety profile manageable: most TRAEs Grade 1-2, no discontinuations due to Grade 3 AST/ALT elevations, 3.7% discontinuation rate.
FDA feedback supports NDA for platinum resistant/refractory ovarian cancer; plan to enroll 20-25 more patients by Q1 2026.
NDA submission for rezatapopt in ovarian cancer targeted for end of Q1 2027.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.